Verve Therapeutics Inc (NASDAQ: VERV) kicked off on Monday, up 11.13% from the previous trading day, before settling in for the closing price of $6.47. Over the past 52 weeks, VERV has traded in a range of $4.30-$19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 126.44% over the past five years. While this was happening, its average annual earnings per share was recorded 21.22%. With a float of $63.09 million, this company’s outstanding shares have now reached $84.64 million.
Let’s look at the performance matrix of the company that is accounted for 255 employees. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Verve Therapeutics Inc is 25.48%, while institutional ownership is 76.17%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.73 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 21.22% per share during the next fiscal year.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Take a look at Verve Therapeutics Inc’s (VERV) current performance indicators. Last quarter, stock had a quick ratio of 13.05. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 26.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.79 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (NASDAQ: VERV) saw its 5-day average volume 1.85 million, a positive change from its year-to-date volume of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 62.96%. Additionally, its Average True Range was 0.59.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 80.25%, which indicates a significant decrease from 85.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 129.83% in the past 14 days, which was higher than the 86.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.57, while its 200-day Moving Average is $6.95. Nevertheless, the first resistance level for the watch stands at $7.55 in the near term. At $7.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.43. If the price goes on to break the first support level at $6.67, it is likely to go to the next support level at $6.16. The third support level lies at $5.79 if the price breaches the second support level.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
The company with the Market Capitalisation of 644.61 million has total of 84,664K Shares Outstanding. Its annual sales at the moment are 11,760 K in contrast with the sum of -200,070 K annual income. Company’s last quarter sales were recorded 6,870 K and last quarter income was -50,130 K.
